Korean J Lab Med.  2007 Oct;27(5):344-350. 10.3343/kjlm.2007.27.5.344.

Prevalence of Extended-Spectrum beta-lactamases in Escherichia coli and Klebsiella pneumoniae from Daejeon

• Ko CS
• Sung JY
• Koo SH
• Kwon GC
• Shin SY
• Park JW

• KMID: 1781533
• DOI: http://doi.org/10.3343/kjlm.2007.27.5.344

Abstract

BACKGROUND: Extended-spectrum beta-lactamases (ESBLs) are cephalosporinases that confer resistance to a wide variety of oxyimino cephalosporins and create serious therapeutic problems. Although ESBLs have been reported with increasing frequency in Korea, their prevalence and genotypic distribution in Daejeon remain unknown. This study was designed to evaluate the occurrence and genotypic distributions of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Daejeon. METHODS: We tested a total of 427 isolates of E. coli and K. pneumoniae at Chungnam National University Hospital during the period from March to September 2006. ESBL production was determined by the Clinical and Laboratory Standards Institute ESBL confirmatory test; minimum inhibitory concentrations of beta-lactam antibiotics were determined by the broth dilution method. The ceftazidime or cefotaxime resistance of the ESBL-producers was transferred to azide-resistant E. coli J53 by conjugation. Searches for ESBL genes were performed by PCR amplification, and the genotypes of ESBLs were determined by direct nucleotide sequence analysis of the amplified products. The pIs of ESBL were determined by isoelectric focusing. RESULTS: The proportion of ESBL-producers was 10% of the E. coli and 28% of the K. pneumoniae isolates. The prevalence of ESBL-positive isolates was 60% in the intensive care units and 18.7% in the general wards. The most prevalent ESBL genotype in E. coli isolates was blaCTX-M and in K. pneumoniae was blaSHV-12. CONCLUSIONS: E. coli and K. pneumoniae isolates producing SHV-12 or CTX-M-type ESBLs are widespread in Daejeon.

Keyword

ESBL; E. coli; K. pneumoniae; Genotype

MeSH Terms

Anti-Bacterial Agents/therapeutic use
Disk Diffusion Antimicrobial Tests
Drug Resistance, Bacterial
Escherichia coli/*drug effects/enzymology/isolation & purification
Escherichia coli Infections/drug therapy/microbiology
Genotype
Humans
Klebsiella Infections/drug therapy/microbiology
Klebsiella pneumoniae/*drug effects/enzymology/isolation & purification
Korea
*beta-Lactam Resistance
beta-Lactamases/*analysis
beta-Lactams/therapeutic use

Reference

1.Bae IK., Woo GJ., Jeong SH., Park KO., Cho BK., Kim DM, et al. Prevalence of CTX-M-type extended-spectrum β-lactamase-producing Esherichia coli and Klebsiella pneumoniae isolates in Korea. Korean J Clin Microbiol. 2004. 7:48–54. (배일권, 우건조, 정석훈, 박광옥, 조병규, 김둘만 등. 국내에서 분리된 Esherichia coli와 Klebsiella pneumoniae의 CTX-M형 extended-spectrum -lactamase 생성 현황. 대한임상미생물학회지 2004;7: 48-54.).

2.Park JH., Lee SH., Jeong SH., Kim BN., Kim KB., Yoon JD, et al. Characterization and prevalence of Escherichia coli and Klebsiella pneumoniae isolates producing an extended-spectrum β-lactamase from Korean hospitals. Korean J Lab Med. 2003. 23:18–24. (박정호, 이상희, 정석훈, 김빛나, 김경보, 윤종득등. 전국주요병원에서분리된 Escherichia coli와 Klebsiella pneumoniae의 extended-spectrum -lactamase 생성현황과특성. 대한진단검사의학회지 2003;23: 18-24.).

3.Kim YT., Oh KS., Choi SC., Kim TU. Characterization of extended-spectrum β-lactamase genotype TEM, SHV and CTX-M from clinical isolates of Klebsiella pneumoniae and comparison with antibiotic susceptibility test. J Exp Biomed Sci. 2005. 11:389–96.

4.Shin KS., Son BR. Comparison of Vitek ESBL test and other methods for detecting extended-spectrum β-lactamase producing Escherichia coli and Klebsiella Species. Korean J Clin Pathol. 2002. 22:21–6. (신경섭 및 손보라. Escherichia coli와 Klebsiella Species에서 extended-spectrum -lactamase 검출을 위한 Vitek ESBL test와 그외방법의비교. 대한임상병리학회지 2002;22: 21-6.).

5.Hong SG., Kang MS., Choi JR., Lee KW., Chong YS., Kwon OH. Molecular characteristics of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae. Korean J Clin Pathol. 2001. 21:495–504. (홍성근, 강명서, 최종락, 이경원, 정윤섭, 권오헌. 임상검체에서 분리된 Enterobacteriaceae 균종의 extended-spectrum -lactamase 유형및분자역학적특성. 대한임상병리학회지 2001 2001;21: 495-504.).

6.Lee BY., Jeong SH., Jeong TS., Nam HJ., Ji JH., Hong YR. Detection of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. with the Vitek GNS 121 card. Korean J Clin Pathol. 2001. 21:350–4. 이보영, 정석훈, 정태식, 남희준, 지종현, 홍유라. Vitek GNS 121 card를 이용한 extended-spectrum -lactamase 생성 Escherichia coli와 Klebsiella spp. 검출. 대한임상병리학회지 2001;21: 350-4.).

7.Jarlier V., Nicolas MH., Fournier G., Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988. 10:867–78.

8.Cormican MG., Marshall SA., Jones RN. Detection of extended-spectrum beta-lactamase (ESBL)- producing strains by the E test ESBL screen. J Clin Microbiol. 1996. 34:1880–4.

9.Moland ES., Sanders CC., Thomson KS. Can results obtained with commercially available Microscan microdilution panels serve as an indicator of beta-lactamase production among Escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? J Clin Microbiol. 1998. 36:2575–9.

10.Sanders CC., Barry AL., Washington JA., Shubert C., Moland ES., Traczewski MM, et al. Detection of extended-spectrum-beta-lactamase producing memebers of the family Enterobacteriaceae with Vitek ESBL test. J Clin Microbiol. 1996. 34:2997–3001.

11.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. M100-S16. Wayne, Pennsylvania: CLSI;2006.

12.Bedenic B., Randegger C., Boras A., Haechler H. Comparison of five different methods for detection of SHV extended-spectrum beta-lactamases. J Chemother. 2001. 13:24–33.

13.Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001. 14:933–51.

14.Paterson DL., Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005. 18:657–86.

15.Hong SG., Kim SJ., Jeong SH., Chang CH., Cho SR., Ahn JY, et al. Prevalence & diversity of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Korea. Korean J Clin Microbiol. 2003. 6:149–55. (홍성근, 김선주, 정석훈, 장철훈, 조성란, 안지영 등. 국내에서 분리된 extended-spectrum -lactamase 생성 Escherichia coli와 Klebsiella pneumoniae의 빈도 및 유형. 대한임상미생물학회지 2003;6: 149-55.).

16.Song WK., Kim JS., Kim MN., Kim EC., Park YJ., Yong DE, et al. Occurrence and genotypic distributions of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea. Korean J Lab Med. 2002. 22:410–6. (송원근, 김재석, 김미나, 김의종, 박연준, 용동은 등. 한국에서 분리된 plasmid-mediated AmpC β-Lactamase 생성 Escherichia coli와 Klebsiella pneumoniae 빈도와유전자형의분포. 대한진단검사의학회지 2002;22: 410-6.).

17.Lee JH., Bae IK., Kwon SB., Jeong SH., Woo GJ., Lee JW, et al. Prevalence of CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Korea, 2003. Korean J Clin Microbiol. 2004. 7:111–8. (이정현, 배일권, 권수봉, 정석훈, 우건조, 이종욱 등. 국내에서 2003년에 분리된 Eschcerichia coli와 Klebsiella pneumoniae의 CTX-M형 extended-spectrum β-lactamase 생성 현황. 대한임상미생물학회지 2004;7: 111-8.).

18.Kang JH., Bae IK., Kwon SB., Jeong SH., Lee JW., Lee WG, et al. Prevalence of Ambler Class A extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Korea. Korean J Clin Microbiol. 2005. 8:17–25. (강지혜, 배일권, 권수봉, 정석훈, 이종욱, 이위교등. Ambler Class A extended-spectrum -lactamase 생성 Escherichia coli와 Klebsiella pneumoniae의국내분리현황. 대한임상미생물학회지 2005;8: 17-25.).

19.Jacoby GA., Han P. Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 1996. 34:908–11.

20.Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983. 11:315–7.

21.Stobberingh EE., Arends J., Hoogkamp-Korstanje JA., Goessens WH., Visser MR., Buiting AG, et al. Occurrence of extended-spectrum beta-lactamases (ESBL) in Dutch hospitals. Infection. 1999. 27:348–54.

22.Jones RN., Pfaller MA., Doern GV., Erwin ME., Hollis RJ. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. Diagn Microbiol Infect Dis. 1998. 30:215–28.

23.Bradford PA. Extended-spectrum beta-lactamase in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001. 14:933–51.

24.Branger C., Lesimple AL., Bruneau B., Berry P., Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases in a university hospital. J Med Microbiol. 1998. 47:201–9.

25.Yagi T., Kurokawa H., Shibata N., Shibayama K., Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett. 2000. 184:53–6.

26.Pena C., Pujol M., Ardanuy C., Ricart A., Pallares R., Linares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1998. 42:53–8.

27.Kolar M., Latal T., Cermak P., Bartonikova N., Chmelarova E., Sauer P, et al. Prevalence of extended-spectrum beta-lactamase-positive Klebsiella pneumoniae isolates in the Czech Republic. Int J Antimicrob Agents. 2006. 28:49–53.

28.Bassetti M., Cruciani M., Righi E., Rebesco B., Fasce R., Costa A, et al. Antimicrobial use and resistance among gram-negative bacilli in an Italian intensive care unit (ICU). J Chemother. 2006. 18:261–7.

29.Ambler RP., Coulson AF., Frere JM., Ghuysen JM., Joris B., Forsman M, et al. A standard numbering scheme for the Class A β-lactamases. Biochem. 1991. 276:269–72.

30.Pai HJ. The characteristics of extended-spectrum beta-lactamases in Korean isolates of Enterobacteriaceae. Yonsei Med J. 1998. 39:514–9.

31.Kim J., Kwon Y., Pai H., Kim JW., Cho DT. Survey of Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J Clin Microbiol. 1998. 36:1446–9.

32.Kim J., Lim YM., Rheem I., Lee Y., Lee JC., Seol SY, et al. CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea. FEMS Microbiol Lett. 2005. 245:93–8.

33.Ryoo NH., Kim EC., Hong SG., Park YJ., Lee K., Bae IK, et al. Dissemination of SHV-12 and CTX-M-type extended-spectrum beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Antimicrob Chemother. 2005. 56:698–702.